miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer

摘要: Trastuzumab is established as standard care for patients with HER2-positive breast cancer both in the adjuvant and metastatic setting. However, approximately 50% of do not respond to trastuzumab therapy, therefore new predictive biomarkers are highly warranted. MicroRNAs (miRs) constitute a group their cellular expression can be determined tumor samples by situ hybridization (ISH) analysis. miR-21 prevalent up-regulated has been linked drug resistance clinical vitro settings. To determine patterns high-grade cancers, we examined 22 tumors 15 HER2-negative ISH. The histological examination indicated that patient could divided into 3 major patterns: predominantly stroma, cells or stromal cells. There was no obvious difference between terms intensities. explore possibility levels and/or localization predict patients, analyzed additional 16 from were treated Eight showed recurrence considered resistant. Examination intensities revealed association scores cell population (p=0.69) (p=0.13) recurrent disease after trastuzumab. Thus, our findings show elevated does